News und Analysen
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2020, and provided a business update.
“We made significant
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Simulations Plus Releases GastroPlus® Version 9.8.1
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it
Nature Medicine Publishes First Study Utilizing NanoString’s GeoMx Digital Spatial Profiler Whole Transcriptome Atlas
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the publication of a study in the journal Nature
Novocure Announces Addition to Its Board of Directors
Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Timothy J. Scannell, an experienced executive leader, was elected to Novocure’s board on Feb. 5.
“We are extremely
Agilent to Present at Upcoming Investor Events; Provides Webcast Details for Annual Shareholder Meeting
Agilent Technologies Inc. (NYSE: A) today announced the following webcasts for the investment community.
10th Annual SVB Leerink Global Healthcare Conference
Wednesday, Feb. 24 at 7:40 a.m
Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle
Feb. 8, 2021 -- Illumina, Inc. (NASDAQ: ILMN) has selected nine new genomics companies to join the second global funding cycle of Illumina Accelerator in the U.S. and UK. The global company
Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle
Feb. 8, 2021 -- Illumina, Inc. (NASDAQ: ILMN) has selected nine new genomics companies to join the second global funding cycle of Illumina Accelerator in the U.S. and UK. The global company
Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle
Feb. 8, 2021 -- Illumina, Inc. (NASDAQ: ILMN) has selected nine new genomics companies to join the second global funding cycle of Illumina Accelerator in the U.S. and UK. The global company
ProvideGx® Partners with Apotex Corp. to Stabilize Supply of Three Vital Antibiotics
Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Apotex Corp. to supply three essential antibiotics to healthcare providers, helping to secure the immediate and
Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE® (palbociclib). The certificate
Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE® (palbociclib). The certificate
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting
Lantheus Holdings, Inc. (NASDAQ: LNTH) (the “Company”), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture
Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that two abstracts featuring data from clinical studies evaluating Rubraca® (rucaparib) in metastatic castration-resistant prostate cancer
Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021
Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium
February 4, 2021 -- Today, Illumina, Inc. (NASDAQ:ILMN) announced an agreement with the Belgian Society of Medical Oncology (BSMO) which is running a new national pilot to evaluate the use of
Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium
February 4, 2021 -- Today, Illumina, Inc. (NASDAQ:ILMN) announced an agreement with the Belgian Society of Medical Oncology (BSMO) which is running a new national pilot to evaluate the use of
Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium
February 4, 2021 -- Today, Illumina, Inc. (NASDAQ:ILMN) announced an agreement with the Belgian Society of Medical Oncology (BSMO) which is running a new national pilot to evaluate the use of
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Quidel Opens New Manufacturing Facility to Mass Produce QuickVue® Rapid Antigen Tests for COVID-19
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced the opening
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 3, 2021.
Fourth
Dexcom und Nick Jonas enthüllen den ersten Super Bowl-Werbespot und fordern eine bessere Versorgung von Menschen mit Diabetes
DexCom, Inc. (NASDAQ:DXCM), der weltweit führende Anbieter von kontinuierlicher Blutzuckermessung für Menschen mit Diabetes, hat heute seinen allerersten Super-Bowl-Werbespot mit dem
Dexcom und Nick Jonas enthüllen den ersten Super Bowl-Werbespot und fordern eine bessere Versorgung von Menschen mit Diabetes
DexCom, Inc. (NASDAQ:DXCM), der weltweit führende Anbieter von kontinuierlicher Blutzuckermessung für Menschen mit Diabetes, hat heute seinen allerersten Super-Bowl-Werbespot mit dem
Dexcom and Nick Jonas Unveil First-Ever Super Bowl Commercial, Calling for Better Care for People With Diabetes
DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, debuted today its first-ever Super Bowl commercial, starring multi-platinum recording